zilucoplan sold brand name zilbrysq medication used treatment generalized myasthenia complement inhibitor injected subcutaneously zilucoplan cyclic peptide binds protein complement component inhibits cleavage zilucoplan approved medical use united states october zilucoplan indicated treatment generalized myasthenia gravis adults antiacetylcholine receptor antibody zilucoplan international nonproprietary september committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product zilbrysq intended treatment myasthenia applicant medicinal product ucb pharma zilucoplan granted orphan drug designation us food drug administration fda august ema july httpsenwikipediaorgwikizilucoplan